Результати пошуку - Jeffrey A. Zonder

Уточнити результати
  1. 1
    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin... за авторством Q. Ping Dou, Jeffrey A. Zonder

    Опубліковано 2014
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Clinical development of novel proteasome inhibitors for cancer treatment

    Clinical development of novel proteasome inhibitors for cancer treatment за авторством Huanjie Yang, Jeffrey A. Zonder, Q. Ping Dou

    Опубліковано 2009
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    Exportin 1 inhibition as antiviral therapy

    Exportin 1 inhibition as antiviral therapy за авторством Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi

    Опубліковано 2020
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    Circular RNAs in acute myeloid leukemia

    Circular RNAs in acute myeloid leukemia за авторством Vijendra K. Singh, Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis за авторством Jeffrey A. Zonder, Bart Barlogie, Brian G.M. Durie, Jason McCoy, John Crowley, Mohamad A. Hussein

    Опубліковано 2006
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  6. 6
    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety за авторством Ashraf Badros, Ravi Vij, Thomas C. Martin, Jeffrey A. Zonder, Lori Kunkel, Z. Wang, S. Lee, Alvin Wong, Rubén Niesvizky

    Опубліковано 2013
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma за авторством Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William Bensinger, Han Ting Ding, John Fry, Daniel Afar, Anil Singhal

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study за авторством Suzanne Lentzsch, Galina Lagos, Raymond L. Comenzo, Jeffrey A. Zonder, Keren Osman, Samuel Pan, Divaya Bhutani, Silva Pregja, Vaishali Sanchorawala, Heather Landau

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) за авторством Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma за авторством Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander, Rafaël Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase... за авторством Jesús G. Berdeja, Sundar Jagannath, Jeffrey A. Zonder, Ashraf Badros, Jonathan L. Kaufman, Robert Manges, Manish Gupta, Amol Tendolkar, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Ravi Vij

    Опубліковано 2015
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function за авторством Meletios Α. Dimopoulos, Adrián Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Reece, Marta Olesnyckyj, Zhinuan Yu, Donna M. Weber

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials за авторством Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K. Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma за авторством Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William Bensinger, Brandi Hilder, Selena Rush, Duncan Walker, Brian Tunquist, Kevin Litwiler, Mieke Ptaszynski, Robert Z. Orlowski, Sagar Lonial

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis

    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis за авторством Jack Khouri, Andrew Kin, Bicky Thapa, Frederic J. Reu, Naresh Bumma, Christy Samaras, Hien Liu, Mary Ann Karam, Janice Reed, Saveta Mathur, Beth Faiman, Georgia Devries, Jeffrey A. Zonder, Jason Valent

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus state... за авторством Charalampia Kyriakou, Sean Molloy, Frank D. Vrionis, Ronald Alberico, L. Bastian, Jeffrey A. Zonder, Sergio Giralt, Noopur Raje, Robert A. Kyle, David Roodman, Meletios Α. Dimopoulos, S. Vincent Rajkumar, Brian Durie, Evangelos Terpos

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent

    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent за авторством Benjamin A. Derman, Ankit Kansagra, Jeffrey A. Zonder, Andrew Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej Jakubowiak

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction за авторством Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David C. Seldin, Brendan M. Weiss, Jeffrey A. Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, Gene G. Kinney, Martin Koller, Dale B. Schenk, Spencer Guthrie, Michaela Liedtke

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis за авторством Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

    Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 o... за авторством Suzanne Lentzsch, Amy K. O’Sullivan, Ryan Kennedy, Mohammad Abbas, Lijun Dai, Silvana Pregja, Steve Burt, Michael Boyiadzis, G. David Roodman, Markus Y. Mapara, Mounzer Agha, John Waas, Yongli Shuai, Daniel P. Normolle, Jeffrey A. Zonder

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: